patisiran (Rx)

Brand and Other Names:Onpattro
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lipid complex injection

  • 2mg/mL (5mL-vial)

Amyloidosis

Indicated for treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults

Dose based on actual body weight

<100 kg: 0.3 mg/kg IV q3Weeks

≥100 kg: 30 mg IV q3Weeks

Also see Administration

Premedication

  • All patients should receive premedication prior to therapy to reduce risk of infusion-related reactions (IRRs); administer at least 60 minutes prior to start of infusion
  • For premedications not available or not tolerated IV, equivalents may be administered PO
  • Administer on day of patisiran infusion
    • Administer at least 60 minutes prior to start of infusion
    • IV corticosteroid (eg, dexamethasone 10 mg [IV] or equivalent); if tolerating patisiran infusions but experiencing adverse reactions to corticosteroid premedication, reduce corticosteroid dose by 2.5-mg increments to minimum dose of 5 mg of dexamethasone IV or equivalent
    • PO acetaminophen (500 mg)
    • IV H1 blocker (eg, diphenhydramine 50 mg or equivalent)
    • IV H2 blocker (eg, ranitidine 50 mg or equivalent)
    • Some patients may require additional or higher doses of one or more of the premedications to reduce risk of infusion-related reactions

Dosage Modifications

Hepatic impairment

  • Mild (bilirubin ≤1 x ULN and AST >1 x ULN, or bilirubin >1-1.5 x ULN): No dose adjustment necessary
  • Moderate-to-severe: Safety and efficacy not established

Renal impairment

  • Mild-to-moderate (estimated glomerular filtration rate [eGFR] ≥30 to <90 mL/min/1.73m²): No dose adjustment necessary
  • Severe or end-stage renal disease: Safety and efficacy not established

Safety and efficacy not established

Next:

Adverse Effects

>10%

Upper respiratory tract infections (29%)

Infusion-related reaction (19%)

1-10%

Dyspepsia (8%)

Dyspnea (8%)

Muscle spasms (8%)

Arthralgia (7%)

Erythema (7%)

Bronchitis (7%)

Vertigo (5%)

Blurred vision (3%)

AV heart block (2.7%)

Vitreous floaters (2%)

<1%

Hypotension

Syncope

Extravasation

Previous
Next:

Warnings

Contraindications

None

Cautions

Infusion-related reactions

  • Infusion-related reactions (IRRs) observed in patients receiving therapy
  • Patients should receive premedications on day of infusion, at least 60 min prior to infusion; monitor patients during infusion for signs and symptoms of IRRs; if IRR occurs, consider slowing or interrupting infusion and instituting medical management (eg, corticosteroids or other symptomatic treatment), as clinically indicated (see Dosing)
  • If infusion interrupted, consider resuming at slower infusion rate only if symptoms have resolved; in case of a serious or life-threatening IRR, infusion should be discontinued and not resumed
  • Some patients may benefit from slower infusion rate or, additional or higher doses of other premedications with subsequent infusions to reduce risk

Reduced serum vitamin A levels and recommended supplementation

  • May decrease serum vitamin A levels
  • Vitamin A supplementation advised; higher doses than recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment; serum vitamin A levels do not reflect total vitamin A in the body
  • Refer to ophthalmologist if patient develops ocular symptoms of vitamin A deficiency (eg, night blindness)
Previous
Next:

Pregnancy

Pregnancy

No data are available on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes

Treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised; vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects; effects on the fetus of a reduction in maternal serum transthyretin caused by therapy and of vitamin A supplementation are unknown

Animal data

  • In animal studies, intravenous administration of patisiran lipid complex (patisiran-LC) to pregnant rabbits resulted in developmental toxicity (embryofetal mortality and reduced fetal body weight) at doses that were also associated with maternal toxicity; no adverse developmental effects were observed when patisiran-LC or a rodent-specific (pharmacologically active) surrogate was administered to pregnant rats

Lactation

There is no information regarding presence of drug in human milk, effects on breastfed infant, or on milk production

Consider developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition

In lactating rats, patisiran was not detected in milk; however, lipid components (DLin-MC3-DMA and PEG2000-CDMG) were present in milk

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Contains a double-stranded small interfering ribonucleic acid (siRNA), formulated as a lipid complex for delivery to hepatocytes; drug specifically binds to a genetically conserved sequence in the 3' untranslated region (3'UTR) of mutant and wild-type transthyretin (TTR) messenger RNA (mRNA); drug causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues

Absorption

Steady-state reached by 24 week at recommended dose

Distribution

Protein binding: Low

Vd: 0.26 L/kg; distributes primarily to liver

Metabolism

Metabolized by nucleases to nucleotides of various lengths

Elimination

Half-life: 1.8 days

Total body clearance, steady-state: 3 mL/hr/kg

Excretion: Urine <1%

Previous
Next:

Administration

IV Preparation

Must filter and dilute solution prior to IV infusion; the solution should be prepared by a healthcare professional using aseptic technique

Remove vial from refrigerator and allow to warm to room temperature; do not shake or vortex

Inspect visually for particulate matter and discoloration; do not use if discoloration or foreign particles are present; the product is a white to off-white, opalescent, homogeneous solution; a white to off-white coating may be observed on inner surface of vial, typically at liquid-headspace interface; product quality is not impacted by presence of white to off-white coating

Calculate required dose based on recommended weight-based dosage

Withdraw entire contents of one or more vials into single sterile syringe

Filter solution through a sterile 0.45-micron polyethersulfone (PES) syringe filter into a sterile container

Withdraw required volume of filtered solution from sterile container using a sterile syringe

Dilute required volume of filtered solution into an infusion bag containing 0.9% NaCl for a total volume of 200 mL; use infusion bags that are di(2-ethylhexyl)phthalate-free (DEHPfree)

Gently invert bag to mix solution; do not shake; do not mix or dilute with other drugs

Discard any unused portion

Product does not contain preservatives; the diluted solution should be administered immediately after preparation; if not used immediately, store infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hr (including infusion time); do not freeze

IV Administration

Use a dedicated line with an infusion set containing a 1.2-micron PES in-line infusion filter

Use infusion sets and lines that are DEHP-free

Infuse diluted solution intravenously, via an ambulatory infusion pump, over ~80 minutes, at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to ~3 mL/min for the remainder of the infusion; duration of the infusion may be extended in the event of an IRR

Administer only through a free-flowing venous access line; monitor infusion site for possible infiltration during drug administration; suspected extravasation should be managed according to local standard practice for nonvesicants

Observe patient during infusion and, if clinically indicated, following infusion

After completion of infusion, flush IV line with 0.9% NaCl to ensure that all the drug has been administered

Missed dose

  • If dose is missed, administer as soon as possible
  • If drug is administered within 3 days of missed dose, continue dosing according to original dosing schedule
  • If drug is administered more than 3 days after missed dose, continue dosing q3Weeks thereafter

Storage

Unopened vials: Store at 2-8°C (36-46°F); do not freeze; discard vial if it has been frozen; if refrigeration is not available, store at room temperature up to 25°C (up to 77°F) for up to 14 days

Diluted solution: If not administered immediately after preparation, store infusion bag at room temperature up to 30°C (86°F) for up to 16 hr (including infusion time); do not freeze

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.